Ignite Creation Date:
2024-05-06 @ 7:07 AM
Last Modification Date:
2024-10-26 @ 11:45 AM
Study NCT ID:
NCT02476955
Status:
TERMINATED
Last Update Posted:
2020-09-30
First Post:
2015-06-10
Brief Title:
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
Sponsor:
ArQule Inc a subsidiary of Merck Sharp Dohme LLC a subsidiary of Merck Co Inc Rahway NJ USA
Organization:
ArQule Inc a subsidiary of Merck Sharp Dohme LLC a subsidiary of Merck Co Inc Rahway NJ USA
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Endometrial Cancer |
| Solid Tumors |
| Ovarian Cancer |
Keywords:
| Name | View |
|---|---|
| PIK3CA mutation | View |
| ARQ 092 | View |
| Carboplatin | View |
| Paclitaxel | View |
| AKT inhibitor in combination therapy | View |
| Targeted therapy | View |
| Molecular therapy | View |
| Tyrosine kinase inhibitor TKI | View |
| Receptor tyrosine kinase RTK | View |
| Biomarkers | View |
| Phase 1 - Phase I | View |
| Solid tumors | View |
| Metastatic solid tumors | View |
| Recurrent solid tumors | View |
| Ovarian cancer | View |
| Endometrial cancer | View |
| Cervical cancer | View |
| Triple-negative breast cancer | View |
| AKT kinases | View |
| AKT pathway | View |
| AKT signaling | View |
| AKT inhibitor | View |
| AKT pan inhibitor | View |
| Chemotherapy | View |
| PI3KAKTmTOR signaling pathway | View |
| AKT1 | View |
| AKT2 | View |
| AKT3 | View |
| Phase I Clinical Trial | View |
| Clinical oncology | View |
| Tumor | View |
| AKT1 inhibitor | View |
| AKT2 inhibitor | View |
| AKT3 inhibitor | View |
| AKT1 mutation | View |
| AKT2 mutation | View |
| AKT3 mutation | View |
| AKT1 amplification | View |
| AKT2 amplification | View |
| AKT3 amplification | View |
| Anastrozole | View |
| Estrogen receptor positive | View |